HHSB26120120000421 DOSE-DE ESCALATION/ESCALAATION TRIAL TO IDENTIFY THE LOWEST COMMERCIALLY AVAILABLE DOSE OF LINACLOTIDE THAT MAINTAINS BIOACTIVITY IN RECTAL MUCOSA (PROTOCOL MAY2012-00-01 09/24/201

Mayo Clinic Rochester, Rochester MN

Investigators

Abstract

The proposed Phase I dose ranging clinical trial is designed to identify the lowest commercially available dose of linaclotide that achieves a statistically significant elevation of rectal cGMP after 7 days of administration.